Crohn’s Disease
Crohn’s Disease is a type of inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, and weight loss.
We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.
Health conditions and diseases that the clinical trial is designed to study and treat.
Crohn’s Disease is a type of inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, and weight loss.
Ulcerative Colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the colon, resulting in symptoms such as abdominal pain, diarrhea, and rectal bleeding.
Inflammatory Bowel Diseases (IBD) is a term that encompasses conditions like Crohn’s Disease and Ulcerative Colitis, characterized by chronic inflammation of the gastrointestinal tract, leading to various digestive symptoms.
Chronic Ulcerative Colitis is a long-term form of Ulcerative Colitis that leads to persistent inflammation and ulcers in the colon, causing ongoing symptoms like abdominal pain and diarrhea.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.